Soliris - 2007 FDA approvals

Drug Development: An Overview of the Regulated Clinical Trials Process Used to Bring a New Drug to Market
Join us for a one-hour overview of the regulated clinical trials process used to bring a n
Inside the mHealth Revolution with Welch Allyn: Realizing the Potential of Connected Devices
After launching a line of connected devices, Welch Allyn immediately viewed it as an oppor
Active Directory & the Cloud for Biotech & Pharma
Biotech and pharmaceutical companies are leaders cloud/SaaS technology adoption. This webi
Prepare Your Compliance Systems and Processes for the Physician Payments Sunshine Act
Beginning in 2012, pharmaceutical, biotechnology and medical device companies will be requ

January 9, 2008 — 9:18am ET | By Maureen Martino

Tools

Drug: Soliris (eculizumab)
Indication: Paroxysmal nocturnal hemoglobinuria
Company: Alexion
Approval Date: March 16, 2007

Scoop: Soliris is a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria--a disease in which the immune system attacks the body's own red blood cells.

More news:
Alexion's eculizumab succeeds in Phase III. Report
Alexion shares surge on eculizumab data. Report

SHARE
WITH:

More stories about Alexion Pharmaceuticals Soliris eculizumab

Most Popular Stories

Webinars

Featured Jobs

Events

Soliris - 2007 FDA approvals

THE FIERCEMARKETS NETWORK